In regard to potential alternative biomarkers, minichromosome maintenance 6 (MCM6) has recently been proposed as a marker with higher expression in more aggressive breast cancers—including luminal B, HER2-enriched, and triple-negative cancers—with discrimination performance similar to or perhaps better than Ki-67 [184,185]. This evidence concerns the gene MKI67 and breast cancer.